Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vytrus BiotechXMAD:VYT -2.63%66 3-1 Month Momentum % is 0.89% as of Aug. 27, 2026. GuruFocus rates XMAD:VYT with a GF Score™ of 66/100 and a GF Value™ of €5.68 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,384 Biotechnology companies, Vytrus Biotech ranks better than 67.99% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-27), Vytrus Biotech's 3-1 Month Momentum % is 0.89%.
The industry rank for Vytrus Biotech's 3-1 Month Momentum % or its related term are showing as below:
XMAD:VYT's 3-1 Month Momentum % is ranked better than 67.99% of 1384
companies
in the Biotechnology industry
Industry Median: -9.34
vs XMAD:VYT: 0.89
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vytrus Biotech 3-1 Month Momentum % Related Terms
XMAD:VYT vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Vytrus Biotech's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vytrus Biotech (XMAD:VYT) has a 3-1 Month Momentum % of 0.89% as of Aug. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vytrus Biotech and its competitors. According to the industry distribution chart, Vytrus Biotech ranks #443 out of 1384 companies in the Biotechnology industry, placing it in the top 32%.
Is Vytrus Biotech's 3-1 Month Momentum % too high?
Vytrus Biotech's current 3-1 Month Momentum % is 0.89%. Based on the distribution chart, Vytrus Biotech ranks #443 out of 1384 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #443 out of 1384 companies for 3-1 Month Momentum %. This puts Vytrus Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vytrus Biotech and its competitors. Vytrus Biotech's current 3-1 Month Momentum % is 0.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.68, compared to a current price of €16.65 — trading 193.1% above its estimated fair value. The current 3-1 Month Momentum % is 0.89%. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current 3-1 Month Momentum % is 0.89% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €16.65 is trading 193.1% above its estimated GF Value™ of €5.68.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
3-1 Month Momentum %: 0.89%
GF Value™: €5.68 vs. price of €16.65 (193.1% above fair value)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score
Get the complete analysis for XMAD:VYT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
